Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP332859.RAf2IfYGitUSFHxZ7ozO5nSsu0qv_9u_4nugGbbhtLTCU130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP332859.RAf2IfYGitUSFHxZ7ozO5nSsu0qv_9u_4nugGbbhtLTCU130_assertion type Assertion NP332859.RAf2IfYGitUSFHxZ7ozO5nSsu0qv_9u_4nugGbbhtLTCU130_head.
- NP332859.RAf2IfYGitUSFHxZ7ozO5nSsu0qv_9u_4nugGbbhtLTCU130_assertion description "[Together, our findings suggest that selectively targeting tumor-elicited myeloid cells or versican represents a potential therapeutic strategy for combating metastatic disease.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP332859.RAf2IfYGitUSFHxZ7ozO5nSsu0qv_9u_4nugGbbhtLTCU130_provenance.
- NP332859.RAf2IfYGitUSFHxZ7ozO5nSsu0qv_9u_4nugGbbhtLTCU130_assertion evidence source_evidence_literature NP332859.RAf2IfYGitUSFHxZ7ozO5nSsu0qv_9u_4nugGbbhtLTCU130_provenance.
- NP332859.RAf2IfYGitUSFHxZ7ozO5nSsu0qv_9u_4nugGbbhtLTCU130_assertion SIO_000772 22282653 NP332859.RAf2IfYGitUSFHxZ7ozO5nSsu0qv_9u_4nugGbbhtLTCU130_provenance.
- NP332859.RAf2IfYGitUSFHxZ7ozO5nSsu0qv_9u_4nugGbbhtLTCU130_assertion wasDerivedFrom befree-20150227 NP332859.RAf2IfYGitUSFHxZ7ozO5nSsu0qv_9u_4nugGbbhtLTCU130_provenance.
- NP332859.RAf2IfYGitUSFHxZ7ozO5nSsu0qv_9u_4nugGbbhtLTCU130_assertion wasGeneratedBy ECO_0000203 NP332859.RAf2IfYGitUSFHxZ7ozO5nSsu0qv_9u_4nugGbbhtLTCU130_provenance.